A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts
Journal of Opioid Management · 15.01.2018 · 7 (1) · 11-20
DOI: 10.5055/jom.2011.0044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Opioid Management, online erschienen am 15.01.2018. Verfasst von Kushal Jain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Lund University, Sweden. drkushal80@gmail.com. Die Arbeit wurde bisher 20-mal zitiert (Crossref).
Abstract (Originalsprache)
Objectives
To compare the efficacy of memantine with buprenorphine in the suppression of naloxone-precipitated acute withdrawal in heroin-dependent male subjects in an inpatient setting.
Setting
Inpatient unit of tertiary level deaddiction facility.
Participants
Forty-five treatment-seeking heroin-dependent males.
Interventions
Subjects stabilized on 650 mg of dextropropoxyphene for 5 days were randomly divided into two groups on the sixth day: group A (n = 25) received 20 mg of memantine with buprenorphine placebo, and group B (n = 20) received 2 mg of buprenorphine with memantine placebo. Acute withdrawals were precipitated with naloxone (0.4 mg, intravenously) and were assessed using subjective and objective opioid withdrawal scales (SOWS and OOWS) and two separate visual analogue scales (VASs) for pain and dysphoria at baseline prior to test drug administration and again after the precipitation of acute withdrawal.Main outcome measures: Severity of precipitated opioid withdrawals.
Results
Baseline opioid withdrawal symptoms in both groups did not differ significantly. After the precipitation of acute withdrawal, there were no significant differences between subjects in both groups on OOWS and both VASs but showed significant difference on SOWS. When changes in ratings from baseline (and after naloxone-precipitated acute withdrawal) were compared between the two groups, a significant difference in the change in SOWS scores was observed with greater decrease in withdrawal scores in the buprenorphine group.
Conclusions
Memantine has comparable efficacy to buprenorphine in the suppression of objective signs of naloxone-precipitated acute opioid withdrawal; however, its role in the suppression of subjective symptoms is debatable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Lund University, Sweden. drkushal80@gmail.com
Zitieren
APA
Jain, K., Jain, R., & Dhawan, A. (2018). A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. Journal of Opioid Management, 7(1), 11-20. https://doi.org/10.5055/jom.2011.0044
Vancouver
Jain K, Jain R, Dhawan A. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. Journal of Opioid Management. 2018;7(1):11-20. doi:10.5055/jom.2011.0044
BibTeX
@article{Jain2018,
author = {Jain, Kushal and Jain, Raka and Dhawan, Anju},
title = {A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts},
journal = {Journal of Opioid Management},
year = {2018},
volume = {7},
number = {1},
pages = {11--20},
doi = {10.5055/jom.2011.0044}
}
EUVIMED